Award

Identifying High Carbon Footprint Medicines

NHS ENGLAND & NHS IMPROVEMENT

This public procurement record has 1 release in its history.

Award

09 Feb 2022 at 10:22

Summary of the contracting process

NHS England & NHS Improvement is conducting a procurement process titled "Identifying High Carbon Footprint Medicines" aimed at assessing the carbon emissions associated with specific medicines. This project aligns with the NHS's commitments set out in the 2019 Long Term Plan and aims to achieve net zero carbon emissions by 2040 for direct emissions and by 2045 for its full scope, including the supply chain. The tender phase concluded on 14th January 2022, with a contract period starting on 10th February 2022 and ending on 10th May 2022. The procurement method used is a limited competitive quotation, with a total contract value of £50,000, where £48,000 has been awarded to Carbon Trust Advisory Limited for their services in this project.

This tender presents significant opportunities for businesses involved in environmental consultancy, specifically in the pharmaceutical sector. Companies that focus on carbon footprint assessment, sustainability strategies, and the environmental impacts of manufacturing are particularly well-suited to compete. Engaging with such projects not only fosters business growth but also contributes to the broader goal of reducing the NHS's carbon emissions, thereby aligning corporate activities with sustainable practices in the health industry.

Find more tenders on our Open Data Platform.
How relevant is this notice?

D3 Tenders Premium

Win More Public Sector Contracts

AI-powered tender discovery, pipeline management, and market intelligence — everything you need to grow your public sector business.

Notice Title

Identifying High Carbon Footprint Medicines

Notice Description

Need for the project 1. The 2019 NHS Long Term Plan set sustainability commitments for the NHS, which are elaborated in the 'Delivering a Net Zero National Health Service' report. 2. The 2020 'Delivering a Net Zero National Health Service' report committed the NHS to reaching net zero carbon emissions across the emissions that it directly controls by 2040 (with an 80% reduction by 2032) and for its full scope, including its supply chain, by 2045 (with an 80% reduction by 2039). Medicines account for 25% of NHS carbon emissions, 5 percentage points being direct emissions, e.g. from inhalers and anaesthetic gases, and 20% being from other medicines, including those emissions embedded in the medicines supply chain. 3. Whilst several options exist, it is unclear which methodology is the most practical and usable for the NHS in assessing the carbon footprint of specific medicines, which is essential for determining the next steps in the NHS's strategy to reduce emissions from medicines, particularly those beyond direct emissions from inhalers and anaesthetics. Example of options considered to date: * Process mass intensity (PMI) is one methodology of assessing the environmental impact of chemical and pharmaceutical development processes. PMI uses the total mass of input materials required to produce a unit of the target chemical product. It has the advantage of being relatively easy to calculate, where the manufacturing process data is readily available, but has the limitation of being a proxy and still requires manufacturing information * Top down economic modelling of medicine supply chains assumes the same intensity of carbon emissions per unit of monetary value. This homogeneity assumption is a well-known limitation of input/output modelling. 4. There is limited information available on emissions from active pharmaceutical ingredients (APIs) and the manufacture of them. It is important to note that the API is only one component that contributes to the emissions of medicine manufacturing - many other chemicals and processes could be used in medicine manufacture, which must also be included in the assessment of emissions per medicine. 5. There are broader impacts of the production and manufacture of medicines on the environment. The focus of this methodology must be carbon emissions (CO2e), but broader environmental impacts should also be considered to avoid unintended environmental consequences. 6. A number of factors must be taken into account when defining medicines related policy measures to reduce carbon emissions. It is critical that any change in policy results in no diminution in patient outcome (ideally an improvement in patient outcomes will be realised). Other factors such as financial impact or supply chain resilience must also be considered. The objective of this project is therefore to understand the best approach to assess carbon emissions from specific medicines or groups of medicines (e.g. by class)

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/e64e8702-500d-4e17-8432-57ff960d17c8
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Limited
Procurement Method Details
Competitive quotation (below threshold)
Tender Suitability
SME, VCSE
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services


CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£50,000 Under £100K
Lots Value
Not specified
Awards Value
£48,000 Under £100K
Contracts Value
Not specified

Notice Dates

Publication Date
9 Feb 20224 years ago
Submission Deadline
14 Jan 2022Expired
Future Notice Date
Not specified
Award Date
9 Feb 20224 years ago
Contract Period
10 Feb 2022 - 10 May 2022 1-6 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Not Specified
Awards Status
Active
Contracts Status
Not Specified

Contracting Authority (Buyer)

Main Buyer
NHS ENGLAND & NHS IMPROVEMENT
Contact Name
Andrew Powell
Contact Email
andrew.powell14@nhs.net
Contact Phone
07970786424

Buyer Location

Locality
LEEDS
Postcode
LS2 7UE
Post Town
Leeds
Country
England

Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE42 Leeds
Delivery Location
TLC North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLJ South East (England), TLK South West (England)

Local Authority
Leeds
Electoral Ward
Little London & Woodhouse
Westminster Constituency
Leeds Central and Headingley

Supplier Information

Number of Suppliers
1
Supplier Name

CARBON TRUST ADVISORY

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

Download

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8-2022-02-09T10:22:41Z",
    "date": "2022-02-09T10:22:41Z",
    "ocid": "ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8",
    "language": "en",
    "initiationType": "tender",
    "tender": {
        "id": "CF-0628600D0O000000rwimUAA1",
        "title": "Identifying High Carbon Footprint Medicines",
        "description": "Need for the project 1. The 2019 NHS Long Term Plan set sustainability commitments for the NHS, which are elaborated in the 'Delivering a Net Zero National Health Service' report. 2. The 2020 'Delivering a Net Zero National Health Service' report committed the NHS to reaching net zero carbon emissions across the emissions that it directly controls by 2040 (with an 80% reduction by 2032) and for its full scope, including its supply chain, by 2045 (with an 80% reduction by 2039). Medicines account for 25% of NHS carbon emissions, 5 percentage points being direct emissions, e.g. from inhalers and anaesthetic gases, and 20% being from other medicines, including those emissions embedded in the medicines supply chain. 3. Whilst several options exist, it is unclear which methodology is the most practical and usable for the NHS in assessing the carbon footprint of specific medicines, which is essential for determining the next steps in the NHS's strategy to reduce emissions from medicines, particularly those beyond direct emissions from inhalers and anaesthetics. Example of options considered to date: * Process mass intensity (PMI) is one methodology of assessing the environmental impact of chemical and pharmaceutical development processes. PMI uses the total mass of input materials required to produce a unit of the target chemical product. It has the advantage of being relatively easy to calculate, where the manufacturing process data is readily available, but has the limitation of being a proxy and still requires manufacturing information * Top down economic modelling of medicine supply chains assumes the same intensity of carbon emissions per unit of monetary value. This homogeneity assumption is a well-known limitation of input/output modelling. 4. There is limited information available on emissions from active pharmaceutical ingredients (APIs) and the manufacture of them. It is important to note that the API is only one component that contributes to the emissions of medicine manufacturing - many other chemicals and processes could be used in medicine manufacture, which must also be included in the assessment of emissions per medicine. 5. There are broader impacts of the production and manufacture of medicines on the environment. The focus of this methodology must be carbon emissions (CO2e), but broader environmental impacts should also be considered to avoid unintended environmental consequences. 6. A number of factors must be taken into account when defining medicines related policy measures to reduce carbon emissions. It is critical that any change in policy results in no diminution in patient outcome (ideally an improvement in patient outcomes will be realised). Other factors such as financial impact or supply chain resilience must also be considered. The objective of this project is therefore to understand the best approach to assess carbon emissions from specific medicines or groups of medicines (e.g. by class)",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "85100000",
            "description": "Health services"
        },
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "postalCode": "LS2 7UE"
                    },
                    {
                        "region": "England",
                        "countryName": "United Kingdom"
                    }
                ]
            }
        ],
        "minValue": {
            "amount": 48000,
            "currency": "GBP"
        },
        "value": {
            "amount": 50000,
            "currency": "GBP"
        },
        "procurementMethod": "limited",
        "procurementMethodDetails": "Competitive quotation (below threshold)",
        "tenderPeriod": {
            "endDate": "2022-01-14T12:00:00Z"
        },
        "contractPeriod": {
            "startDate": "2022-02-10T00:00:00Z",
            "endDate": "2022-05-10T23:59:59+01:00"
        },
        "suitability": {
            "sme": true,
            "vcse": true
        },
        "mainProcurementCategory": "services"
    },
    "parties": [
        {
            "id": "GB-CFS-185604",
            "name": "NHS England & NHS Improvement",
            "identifier": {
                "legalName": "NHS England & NHS Improvement"
            },
            "address": {
                "streetAddress": "Quarry House",
                "locality": "Leeds",
                "postalCode": "LS2 7UE",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Andrew Powell",
                "email": "andrew.powell14@nhs.net",
                "telephone": "07970786424"
            },
            "roles": [
                "buyer"
            ]
        },
        {
            "id": "GB-CFS-197395",
            "name": "Carbon Trust Advisory Limited",
            "identifier": {
                "legalName": "Carbon Trust Advisory Limited"
            },
            "address": {
                "streetAddress": "4th Floor Dorset House, 27-45 Stamford Street, London, SE1 9NT, London, SE1 9NT"
            },
            "details": {
                "scale": "large",
                "vcse": false
            },
            "roles": [
                "supplier"
            ]
        }
    ],
    "buyer": {
        "id": "GB-CFS-185604",
        "name": "NHS England & NHS Improvement"
    },
    "awards": [
        {
            "id": "ocds-b5fd17-c7768404-b9c7-4da9-9df8-1ed2d0455aa8-1",
            "status": "active",
            "date": "2022-02-10T00:00:00Z",
            "datePublished": "2022-02-09T10:22:41Z",
            "value": {
                "amount": 48000,
                "currency": "GBP"
            },
            "suppliers": [
                {
                    "id": "GB-CFS-197395",
                    "name": "Carbon Trust Advisory Limited"
                }
            ],
            "contractPeriod": {
                "startDate": "2022-02-10T00:00:00Z",
                "endDate": "2022-05-10T23:59:59+01:00"
            },
            "documents": [
                {
                    "id": "1",
                    "documentType": "awardNotice",
                    "description": "Awarded contract notice on Contracts Finder",
                    "url": "https://www.contractsfinder.service.gov.uk/Notice/e64e8702-500d-4e17-8432-57ff960d17c8",
                    "datePublished": "2022-02-09T10:22:41Z",
                    "format": "text/html",
                    "language": "en"
                }
            ]
        }
    ]
}